Crinetics Pharmaceuticals (NASDAQ: CRNX) furnishes Q3 2025 results release

Rhea-AI Filing Summary

Crinetics Pharmaceuticals submitted a current report to note that it has released financial results for the period ended September 30, 2025. The company issued a press release on November 6, 2025 summarizing its operations and financial condition for that period, and that release is included as an exhibit to this report. The company also clarifies that the information in this report and the attached press release is being furnished rather than filed, which limits how it is treated under certain securities law liability provisions.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001658247false00016582472025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________

FORM 8-K

_________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

_________________________________________________________

Crinetics Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

_________________________________________________________

Delaware			001-38583			26-3744114
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
6055 Lusk Boulevard
San Diego, California						92121
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 450-6464

(Former Name or Former Address, if Changed Since Last Report)

_________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

CRNX

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended September 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.						Description
99.1						Press Release dated November 6, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									Crinetics Pharmaceuticals, Inc.
Date:			November 6, 2025			By:			/s/ R. Scott Struthers, Ph.D.
									R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

FAQ

What did Crinetics Pharmaceuticals (CRNX) disclose in this 8-K?

Crinetics Pharmaceuticals disclosed that it issued a press release reporting its financial results for the period ended September 30, 2025, and furnished that press release as an exhibit.

Which period do the latest Crinetics Pharmaceuticals (CRNX) results cover?

The press release furnished with this report covers Crinetics Pharmaceuticals’ financial results for the period ended September 30, 2025.

Is the Crinetics Pharmaceuticals (CRNX) earnings press release considered filed with the SEC?

No. The company states that the information in this report, including the press release, is furnished under SEC rules and is not deemed filed for purposes of certain Exchange Act liability provisions.

What exhibit did Crinetics Pharmaceuticals (CRNX) attach to this 8-K?

Crinetics Pharmaceuticals attached Exhibit 99.1, which is the press release dated November 6, 2025, and Exhibit 104, the cover page interactive data file.

Which SEC item does this Crinetics Pharmaceuticals (CRNX) 8-K relate to?

The report is filed under Item 2.02, Results of Operations and Financial Condition, reflecting the release of quarterly financial results.

Who signed the Crinetics Pharmaceuticals (CRNX) 8-K?

The report was signed on behalf of Crinetics Pharmaceuticals by R. Scott Struthers, Ph.D., the company’s President and Chief Executive Officer.